31.05.2025 13:17:03
|
Merck's KEYTRUDA Combo Cuts Risk By 35% In First-Line PD-L1+ Metastatic TNBC, Phase 3 Study Confirms
(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive Score [CPS] =10) inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (TNBC), as determined by an FDA-approved test.
KEYTRUDA, when given in combination with Gilead's TROP2 antibody-drug conjugate (ADC) Trodelvy, resulted in a median progression-free survival (PFS) of 11.2 months versus 7.8 months when KEYTRUDA was given in combination with chemotherapy.
The safety profile of KEYTRUDA plus Trodelvy in this study was consistent with the known safety profile of each agent. No new safety signals were identified with the combination.
The data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
20:34 |
Dow Jones-Handel aktuell: Dow Jones zum Ende des Freitagshandels in Grün (finanzen.at) | |
18:04 |
Freundlicher Handel in New York: Dow Jones am Freitagnachmittag stärker (finanzen.at) | |
16:03 |
Dow Jones-Handel aktuell: Dow Jones klettert mittags (finanzen.at) | |
14:03 |
Freundlicher Handel in New York: Dow Jones beginnt Freitagssitzung in der Gewinnzone (finanzen.at) | |
05.06.25 |
NYSE-Handel Dow Jones verbucht letztendlich Abschläge (finanzen.at) | |
05.06.25 |
Gewinne in New York: So performt der Dow Jones aktuell (finanzen.at) | |
05.06.25 |
Zuversicht in New York: Dow Jones-Anleger greifen mittags zu (finanzen.at) | |
05.06.25 |
Anleger in New York halten sich zurück: Dow Jones zum Handelsstart schwächer (finanzen.at) |